Avamys Dosing for Children
For children aged 2-11 years with allergic rhinitis, Avamys (fluticasone furoate nasal spray) should be dosed at 1-2 sprays (27.5-55 µg) per nostril once daily. 1
Age-Specific Dosing Algorithm
Children 2-11 Years Old
- Starting dose: 1 spray per nostril once daily (27.5 µg total dose)
- Maximum dose: 2 sprays per nostril once daily (55 µg total dose)
- Timing: Administer once daily, preferably in the morning
Children ≥12 Years Old
- Dose: 2 sprays per nostril once daily (55 µg total dose)
Clinical Context
The American Academy of Otolaryngology-Head and Neck Surgery guidelines specifically list fluticasone furoate (Veramyst/Avamys) as FDA-approved for children as young as 2 years of age for both seasonal and perennial allergic rhinitis. 1 The flexible dosing range (1-2 sprays) in the 2-11 year age group allows clinicians to start at the lower dose and titrate up based on symptom control.
Safety Profile in Children
Clinical trials in pediatric patients aged 2-11 years demonstrate that fluticasone furoate is well-tolerated with a favorable safety profile. 2, 3 The most common adverse effects include:
- Epistaxis (nosebleeds)
- Headache
- Pharyngolaryngeal pain
- Nasal ulceration
- Back pain
- Pyrexia
- Cough
Important safety consideration: Studies evaluating growth effects show that fluticasone furoate, mometasone furoate, and fluticasone propionate at recommended doses demonstrate no adverse effects on growth in children, unlike beclomethasone dipropionate at twice the recommended dose. 1, 4 This makes fluticasone furoate a prudent choice for long-term use in pediatric patients.
Practical Administration Tips
- Direct the spray away from the nasal septum to minimize risk of septal perforation
- The medication requires dry nasal passages before application for optimal absorption
- Effects typically begin within hours but maximal benefit may take several days of consistent use
- Once-daily dosing improves adherence compared to twice-daily alternatives
Clinical Efficacy
While fluticasone furoate 55 µg once daily demonstrated statistically significant improvement in nasal symptoms in children aged 2-11 years with perennial allergic rhinitis, 2 a 2023 comprehensive review noted that the clinical effect size may not reach the minimal clinically important difference threshold in all studies. 5 However, the medication remains guideline-recommended and FDA-approved for this indication, with the practical advantage of once-daily dosing and established safety profile.